Other Content

Correction: Diabetes management


 

Information was omitted from Table 1 on page 596 of the article, Makin V, Lansang MC. Diabetes management: beyond hemoglobin A 1c (Cleve Clin J Med 2019; 86[9]:595–600, doi:10.3949/ccjm.86a.18031).

The sodium-glucose cotransporter 2 (SGLT2) inhibitors pose a low risk of hypoglyemia, and that should have been noted in the table. The corrected table appears below and online.

Table 1. Advantages of selected type 2 diabetes drugs

Next Article:

Clinical outcomes in diabetes: It’s not just the glucose (and it’s not so simple)

Related Articles